Pilot Study of AVT16 in Healthy Adult Subjects

Inclusion Criteria: * Healthy male and female subjects aged between 18 and 55 years old inclusive * Medical history without evidence of clinically significant disorder, condition or disease that would pose a risk to subject safety * Haematology and biochemistry tests within normal range Exclusion Criteria: * History of relevant drug and/or food allergies * History of hypersensitivity to vedolizumab, AVT16 of their constituents * Past or concurrent medical conditions that could potentially increase subject's risks or interfere with study evaluations